GSI Group Inc. Form 10-Q Summary
Entity note: The supplied filing is for GSI Group Inc., not Novanta Inc. The filing reports the quarter ended June 28, 2013, and was signed August 6, 2013. Financial amounts below are in U.S. dollars.
Business context and reporting period
GSI designs and sells precision photonics, motion-control, and medical imaging products, primarily to original equipment manufacturers. Following its January 2013 acquisition of NDS Surgical Imaging for $82.7 million, the company reported two segments: Laser Products and Precision Technologies. Semiconductor Systems and Laser Systems were reported as discontinued operations.
Financial performance and liquidity
| Metric | Q2 2013 | Q2 2012 | First half 2013 | First half 2012 |
|---|---|---|---|---|
| Sales | $85.3 million | $70.4 million | $168.4 million | $135.6 million |
| Gross profit / margin | $34.5 million / 40.4% | $30.7 million / 43.6% | $67.7 million / 40.2% | $58.3 million / 43.0% |
| Operating income | $4.3 million | $5.1 million | $5.3 million | $7.9 million |
| Income from continuing operations | $0.8 million | $4.5 million | $2.3 million | $5.5 million |
| Net income (loss) attributable to GSI | $(0.9) million | $4.9 million | $1.2 million | $6.3 million |
| Diluted EPS from continuing operations | $0.02 | $0.13 | $0.07 | $0.16 |
- Reported sales grew 21.2% in Q2 and 24.2% in the first half, primarily reflecting NDS. Excluding NDS and foreign exchange, sales declined 1.7% and 0.6%, respectively.
- Q2 discontinued operations incurred a $1.4 million loss, plus a $0.3 million after-tax disposal loss, contributing to the consolidated net loss.
- First-half operating cash flow was $17.7 million, versus $18.9 million a year earlier. Investing cash outflow was $73.4 million, including the NDS acquisition; financing cash inflow was $43.8 million.
- Cash and equivalents were $52.1 million at quarter-end, down from $65.8 million at year-end 2012. Total debt was $95.3 million, including $46.3 million of term loans and $49.0 million drawn on the revolver. An additional $26.0 million was available under the revolver.
- The company reported compliance with credit covenants: leverage ratio 1.97 against a maximum 2.75, and fixed-charge coverage ratio 3.43 against a minimum 1.50. Management said it expected operating cash flows to fund needs for at least the next 12 months.
Material changes versus prior comparable periods
- NDS contributed $16.7 million of Q2 sales and $35.1 million of first-half sales. Its acquisition drove Precision Technologies’ reported sales growth, while that segment’s margins fell from 50.0% to 42.1% in Q2 and from 47.3% to 41.7% for the first half.
- Consolidated gross margin declined 3.2 percentage points in Q2 and 2.8 points in the first half. Management cited product mix, acquired-intangible amortization, and NDS inventory fair-value adjustments.
- Operating income fell despite higher sales, reflecting acquisition-related amortization and inventory adjustments, higher operating costs, and the business mix. Q2 income tax expense was $2.5 million; the reported effective tax rate on continuing operations was 74.5% for Q2 and 53.0% for the first half.
- Debt increased from $50.0 million at December 31, 2012, principally to help fund NDS. The company recorded $28.9 million of goodwill and $37.0 million of acquired identifiable intangible assets from the acquisition.
- Laser Products’ Q2 sales were essentially flat year over year; Precision Technologies’ organic sales declined, partly reflecting a prior-year data-storage customer program that did not repeat. Scanning solutions sales nearly doubled, according to management.
Outlook, commentary, risks, and unusual items
- No specific revenue, earnings, or margin guidance was provided. Management expected $1.0 million to $1.5 million of additional cash restructuring charges during the remainder of 2013, following a post-NDS integration and cost-reduction program.
- The company expected IRS refunds totaling $11.5 million to $13.5 million in Q3 2013; it had received $9.8 million by the filing date. It also expected tax benefits from certain net operating losses in 2014. Management anticipated that a planned legal-entity restructuring could enable recognition of tax benefits related to NDS.
- The 2011 restructuring program was completed in Q2. The Semiconductor Systems business was sold in May for $8.0 million, subject to working-capital adjustments; GSI recorded a $0.3 million after-tax loss on the sale. A dispute over the working-capital calculation from the earlier Laser Systems sale remained unresolved; management did not consider a loss probable and recorded no accrual.
- A French bankruptcy-related tort claim sought approximately €3.1 million; management did not consider a loss probable and recorded no accrual. The filing also noted ordinary-course legal claims.
- Management identified risks including cyclical customer capital spending, customer concentration in medical components, acquisition integration, product demand and delivery, foreign exchange and interest rates, debt service and refinancing, and the ability to realize intangible-asset and tax benefits. The annual goodwill test found no impairment, but the medical components reporting unit’s fair value exceeded carrying value by only about 10%.
- Disclosure controls were assessed as effective at quarter-end, with no reported material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the registrant identity: the source filing names GSI Group Inc., despite the request metadata naming Novanta Inc.
- Track organic revenue and margins separately from acquisition-driven growth, especially for Precision Technologies and NDS.
- Verify whether the expected IRS refund balance was received and whether the anticipated 2014 tax benefits and planned legal-entity changes materialized.
- Monitor debt, revolver availability, covenant headroom, and cash generation following the NDS acquisition.
- Follow completion of restructuring actions, final acquisition purchase-price allocation, and resolution of the Hans Laser working-capital dispute and French litigation.